Jazz Pharmaceuticals plc Stock Analysis & AI Score
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
Company Information
| Employees | — |
| CEO | — |
| Sector | Healthcare |
| Industry | Biotechnology |
| IPO Date | — |
| Website | — |
| Country | — |
| Exchange | NASDAQ |
SEC Filings
Annual Report (10-K)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Quarterly Report (10-Q)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
ST Score
Jazz Pharmaceuticals plc (JAZZ) holds an ST Score of 53.7 out of 100 (B-), with its strongest factor being Profitability (A+) and its weakest Financial Strength (D-). Analysts rate JAZZ Buy across 48 ratings with a $289.50 average price target (+0.2% vs the current $241.46).
- Strongest
- ProfitabilityA+
- Weakest
- Financial StrengthD-
All factor grades
- ProfitabilityA+
- MomentumA
- ForecastB-
- GrowthC-
- ValuationD-
- Financial StrengthD-
- Piotroski8/9
Contact
JAZZ stock: frequently asked questions
What is JAZZ's ST Score?
Jazz Pharmaceuticals plc (JAZZ) has an ST Score of 53.7 out of 100, an overall grade of B-. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is JAZZ a buy, sell, or hold?
Wall Street's consensus rating on JAZZ is Buy based on 48 analyst ratings. Our own ST Score grades it B- (53.7/100). This is data, not investment advice — always do your own research.
What is JAZZ's valuation grade?
Jazz Pharmaceuticals plc (JAZZ) earns a valuation grade of D-, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is JAZZ's growth grade?
Jazz Pharmaceuticals plc (JAZZ) earns a growth grade of C-, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is JAZZ's profitability grade?
Jazz Pharmaceuticals plc (JAZZ) earns a profitability grade of A+, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is JAZZ's financial strength grade?
Jazz Pharmaceuticals plc (JAZZ) earns a financial strength grade of D-, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is the analyst price target for JAZZ?
The average analyst price target for Jazz Pharmaceuticals plc (JAZZ) is $289.50 from 48 analysts, which is +0.2% versus the recent price of $241.46.
What is JAZZ's Piotroski score?
Jazz Pharmaceuticals plc (JAZZ) has a Piotroski F-Score of 8 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.